<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Hikma Pharmaceuticals Plc — News on 6ix</title>
    <link>https://6ix.com/company/hikma-pharmaceuticals-plc</link>
    <description>Latest news and press releases for Hikma Pharmaceuticals Plc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 23 Mar 2026 11:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/hikma-pharmaceuticals-plc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835e51c78dffbe2df12806c.webp</url>
      <title>Hikma Pharmaceuticals Plc</title>
      <link>https://6ix.com/company/hikma-pharmaceuticals-plc</link>
    </image>
    <item>
      <title>Transaction in Own Shares</title>
      <link>https://6ix.com/company/hikma-pharmaceuticals-plc/news/transaction-in-own-shares-519</link>
      <guid isPermaLink="true">https://6ix.com/company/hikma-pharmaceuticals-plc/news/transaction-in-own-shares-519</guid>
      <pubDate>Mon, 23 Mar 2026 11:00:00 GMT</pubDate>
      <description>Hikma Pharmaceuticals Plc has purchased a total of 1,051,214 ordinary shares during the disclosure period from March 16 to March 20, 2026, as part of its $250 million share repurchase program. The purchases were made on various trading venues, with the highest volume of shares, 384,778, bought on the London Stock Exchange on March 19 at a volume-weighted average price of 1,237.41 pence. Since the program&apos;s inception on February 26, 2026, Hikma has repurchased 3,077,665 shares for £38.4 million, </description>
    </item>
    <item>
      <title>Annual Financial Report and Notice of AGM</title>
      <link>https://6ix.com/company/hikma-pharmaceuticals-plc/news/annual-financial-report-and-notice-of-agm-47</link>
      <guid isPermaLink="true">https://6ix.com/company/hikma-pharmaceuticals-plc/news/annual-financial-report-and-notice-of-agm-47</guid>
      <pubDate>Wed, 18 Mar 2026 10:10:00 GMT</pubDate>
      <description>Hikma Pharmaceuticals PLC has announced the availability of its 2025 Annual Report and Accounts, along with the Notice of the 2026 Annual General Meeting, both of which have been submitted to the National Storage Mechanism and are accessible on the company&apos;s website.
                Disclaimer*</description>
    </item>
    <item>
      <title>Director/PDMR Shareholding</title>
      <link>https://6ix.com/company/hikma-pharmaceuticals-plc/news/directorpdmr-shareholding-640</link>
      <guid isPermaLink="true">https://6ix.com/company/hikma-pharmaceuticals-plc/news/directorpdmr-shareholding-640</guid>
      <pubDate>Wed, 11 Mar 2026 10:09:00 GMT</pubDate>
      <description>Hikma Pharmaceuticals PLC has announced a purchase of 6,200 ordinary shares by a Person Discharging Managerial Responsibilities, Hussein Arkhagha, on March 9, 2026, on the London Stock Exchange. The transaction involved shares priced at £12.00 each, totaling £74,400. This notification is made in accordance with EU Market Abuse Regulation requirements.
                Disclaimer*</description>
    </item>
    <item>
      <title>Total Voting Rights</title>
      <link>https://6ix.com/company/hikma-pharmaceuticals-plc/news/total-voting-rights-153</link>
      <guid isPermaLink="true">https://6ix.com/company/hikma-pharmaceuticals-plc/news/total-voting-rights-153</guid>
      <pubDate>Mon, 02 Mar 2026 16:56:00 GMT</pubDate>
      <description>Hikma Pharmaceuticals PLC has announced that as of 28 February 2026, its issued share capital comprises 221,606,453 ordinary shares with voting rights, excluding 12,833,233 treasury shares. This total figure of 221,606,453 shares will serve as the denominator for shareholders to calculate their notification obligations regarding interests in the company under the UK Financial Conduct Authority&apos;s Disclosure Guidance and Transparency Rules.
                Disclaimer*</description>
    </item>
    <item>
      <title>Launch of Buyback Programme</title>
      <link>https://6ix.com/company/hikma-pharmaceuticals-plc/news/launch-of-buyback-programme-1</link>
      <guid isPermaLink="true">https://6ix.com/company/hikma-pharmaceuticals-plc/news/launch-of-buyback-programme-1</guid>
      <pubDate>Thu, 26 Feb 2026 07:05:00 GMT</pubDate>
      <description>Hikma Pharmaceuticals Plc has launched a share buyback programme of up to US $250 million, excluding stamp duty and expenses, to be completed by 23 September 2026. This initiative, reflecting strong cash generation and balance sheet strength, will be executed in two equal tranches of US $125 million, managed by Citigroup Global Markets Limited and J.P. Morgan Securities plc respectively, with the first tranche commencing immediately and concluding by 9 June 2026. The buyback aims to reduce share</description>
    </item>
    <item>
      <title>Final Results, Share Buyback &amp; Leadership Changes</title>
      <link>https://6ix.com/company/hikma-pharmaceuticals-plc/news/final-results-share-buyback-and-leadership-changes</link>
      <guid isPermaLink="true">https://6ix.com/company/hikma-pharmaceuticals-plc/news/final-results-share-buyback-and-leadership-changes</guid>
      <pubDate>Thu, 26 Feb 2026 07:00:00 GMT</pubDate>
      <description>Hikma Pharmaceuticals Plc reported a 7% increase in Group revenue to $3,349 million for the year ended December 31, 2025, with profit attributable to shareholders rising 12% to $402 million, though operating profit saw an 11% decline to $542 million, largely due to a legal settlement. The company announced a $250 million share buyback program for 2026 and a 5% increase in its total dividend to 84 cents per share, reflecting strong cash flow generation. Leadership changes were also announced, inc</description>
    </item>
    <item>
      <title>Statement regarding Hikma Pharmaceuticals Plc</title>
      <link>https://6ix.com/company/hikma-pharmaceuticals-plc/news/statement-regarding-hikma-pharmaceuticals-plc</link>
      <guid isPermaLink="true">https://6ix.com/company/hikma-pharmaceuticals-plc/news/statement-regarding-hikma-pharmaceuticals-plc</guid>
      <pubDate>Wed, 04 Feb 2026 17:29:00 GMT</pubDate>
      <description>Brookfield Private Capital (DIFC) Limited has issued a statement confirming it does not intend to make an offer for Hikma Pharmaceuticals Plc, in accordance with Rule 2.8 of the UK City Code on Takeovers and Mergers. This announcement means Brookfield and any concert parties are restricted from making a further offer for Hikma for six months, unless specific conditions are met, such as the agreement of Hikma&apos;s board or the announcement of a competing offer from a third party.
                Dis</description>
    </item>
    <item>
      <title>Notice of Results</title>
      <link>https://6ix.com/company/hikma-pharmaceuticals-plc/news/notice-of-results-234</link>
      <guid isPermaLink="true">https://6ix.com/company/hikma-pharmaceuticals-plc/news/notice-of-results-234</guid>
      <pubDate>Tue, 03 Feb 2026 07:00:00 GMT</pubDate>
      <description>Hikma Pharmaceuticals PLC will announce its financial results for the year ended 31 December 2025 on Thursday, 26 February 2026. A recording of the presentation and slide deck will be available on the Group&apos;s website from 7:00 AM GMT, with a live Q&amp;A call for analysts scheduled for 9:30 AM GMT.
                Disclaimer*</description>
    </item>
    <item>
      <title>Hikma announces CEO change and Board appointment</title>
      <link>https://6ix.com/company/hikma-pharmaceuticals-plc/news/hikma-announces-ceo-change-and-board-appointment</link>
      <guid isPermaLink="true">https://6ix.com/company/hikma-pharmaceuticals-plc/news/hikma-announces-ceo-change-and-board-appointment</guid>
      <pubDate>Mon, 15 Dec 2025 07:00:00 GMT</pubDate>
      <description>Hikma Pharmaceuticals Plc announced that Riad Mishlawi is stepping down as CEO and from the Board of Directors, with Executive Chairman Said Darwazah assuming CEO responsibilities immediately. Chief Financial Officer Khalid Nabilsi will join the Board and take on additional management duties. The company confirmed that group guidance for 2025 remains unchanged from its November 6th trading update, and full-year results will be reported on February 26, 2026.
                Disclaimer*</description>
    </item>
    <item>
      <title>Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US</title>
      <link>https://6ix.com/company/hikma-pharmaceuticals-plc/news/hikma-launches-tyzavantm-vancomycin-injection-usp-in-the-us</link>
      <guid isPermaLink="true">https://6ix.com/company/hikma-pharmaceuticals-plc/news/hikma-launches-tyzavantm-vancomycin-injection-usp-in-the-us</guid>
      <pubDate>Mon, 08 Dec 2025 21:13:00 GMT</pubDate>
      <description>Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces the launch of the first-of-its-kind, ready-to-use vancomycin premix with room-temperature stability under the brand name TYZAVAN™ (vancomycin injection, USP).1 TYZAVAN™ is offered in pre-filled ready-to-use bags that will help hospitals, pharmacists, doctors, and nurses treat patients faster, more easily, and with reduced risk. This is another example of how Hikma is using its capabilities as a leading g</description>
    </item>
    <item>
      <title>Holding(s) in Company</title>
      <link>https://6ix.com/company/hikma-pharmaceuticals-plc/news/holdings-in-company-714</link>
      <guid isPermaLink="true">https://6ix.com/company/hikma-pharmaceuticals-plc/news/holdings-in-company-714</guid>
      <pubDate>Tue, 11 Nov 2025 12:13:00 GMT</pubDate>
      <description>Boston Partners, formerly Robeco Investment Management, Inc., has increased its stake in Hikma Pharmaceuticals PLC, crossing a notification threshold on November 3, 2025. The firm now holds 6.16% of the voting rights, representing 13,666,938 shares, up from a previous holding of 5.13% or 11,375,955 shares as of September 30, 2025. This acquisition of voting rights was notified to the issuer on November 4, 2025.
                Disclaimer*</description>
    </item>
    <item>
      <title>November Trading Statement</title>
      <link>https://6ix.com/company/hikma-pharmaceuticals-plc/news/november-trading-statement-1</link>
      <guid isPermaLink="true">https://6ix.com/company/hikma-pharmaceuticals-plc/news/november-trading-statement-1</guid>
      <pubDate>Thu, 06 Nov 2025 07:00:00 GMT</pubDate>
      <description>November Trading Statement.</description>
    </item>
    <item>
      <title>Block listing Interim Review</title>
      <link>https://6ix.com/company/hikma-pharmaceuticals-plc/news/block-listing-interim-review-190</link>
      <guid isPermaLink="true">https://6ix.com/company/hikma-pharmaceuticals-plc/news/block-listing-interim-review-190</guid>
      <pubDate>Wed, 01 Oct 2025 10:45:00 GMT</pubDate>
      <description>Hikma Pharmaceuticals PLC reports the six-monthly return for its block listing as of October 1, 2025. The report pertains to the Hikma Pharmaceuticals PLC 2018 Management Incentive Plan and the 2014 Executive Incentive Plan. The period covered is from April 1, 2025, to September 30, 2025. The balance of unallotted securities under the schemes from the previous return was 311,430 ordinary shares of 10 pence. The block scheme has not been increased since the last return, with an increase of 0 ordi</description>
    </item>
    <item>
      <title>Half-year Report</title>
      <link>https://6ix.com/company/hikma-pharmaceuticals-plc/news/half-year-report-408</link>
      <guid isPermaLink="true">https://6ix.com/company/hikma-pharmaceuticals-plc/news/half-year-report-408</guid>
      <pubDate>Thu, 07 Aug 2025 06:00:00 GMT</pubDate>
      <description>Half-year Report.</description>
    </item>
    <item>
      <title>Publication of Offering Circular</title>
      <link>https://6ix.com/company/hikma-pharmaceuticals-plc/news/publication-of-offering-circular-3</link>
      <guid isPermaLink="true">https://6ix.com/company/hikma-pharmaceuticals-plc/news/publication-of-offering-circular-3</guid>
      <pubDate>Mon, 07 Jul 2025 08:16:00 GMT</pubDate>
      <description>Publication of Offering Circular.</description>
    </item>
    <item>
      <title>Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US</title>
      <link>https://6ix.com/company/hikma-pharmaceuticals-plc/news/hikma-receives-fda-approval-for-tyzavantm-vancomycin-injection-usp-in-the-us</link>
      <guid isPermaLink="true">https://6ix.com/company/hikma-pharmaceuticals-plc/news/hikma-receives-fda-approval-for-tyzavantm-vancomycin-injection-usp-in-the-us</guid>
      <pubDate>Wed, 02 Jul 2025 12:00:00 GMT</pubDate>
      <description>Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announced the approval of a novel formulation of the first-of-its-kind, ready-to-infuse formulation of vancomycin, under the brand name TYZAVAN™ (Vancomycin Injection, USP), by the US Food and Drug Administration (FDA).</description>
    </item>
    <item>
      <title>Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines</title>
      <link>https://6ix.com/company/hikma-pharmaceuticals-plc/news/hikma-pharmaceuticals-usa-announces-dollar1-billion-of-new-us-investment-to-further-expand-its-domestic-manufacturing-and-development-of-essential-generic-medicines</link>
      <guid isPermaLink="true">https://6ix.com/company/hikma-pharmaceuticals-plc/news/hikma-pharmaceuticals-usa-announces-dollar1-billion-of-new-us-investment-to-further-expand-its-domestic-manufacturing-and-development-of-essential-generic-medicines</guid>
      <pubDate>Sat, 28 Jun 2025 15:00:00 GMT</pubDate>
      <description>In its ongoing mission to help meet America&apos;s growing need for high-quality US-made medicines, Hikma Pharmaceuticals USA today announces it will invest $1 billion by 2030 to further expand its US manufacturing and R&amp;D capabilities. This new phase of investment -- America Leans on Hikma: Quality Medicines Manufactured in the USA – will further expand Hikma&apos;s well-established domestic capabilities to develop, produce and deliver a broad range of medicines needed by the US healthcare system to trea</description>
    </item>
    <item>
      <title>Fitch upgrades Hikma to ‘BBB’</title>
      <link>https://6ix.com/company/hikma-pharmaceuticals-plc/news/fitch-upgrades-hikma-to-bbb</link>
      <guid isPermaLink="true">https://6ix.com/company/hikma-pharmaceuticals-plc/news/fitch-upgrades-hikma-to-bbb</guid>
      <pubDate>Thu, 29 May 2025 06:00:00 GMT</pubDate>
      <description>Fitch upgrades Hikma to ‘BBB’.</description>
    </item>
    <item>
      <title>Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection</title>
      <link>https://6ix.com/company/hikma-pharmaceuticals-plc/news/bio-thera-solutions-and-hikma-pharmaceuticals-announce-fda-approval-of-starjemzar-ustekinumab-hmny-injection-a-biosimilar-referencing-stelarar-ustekinumab-injection-1</link>
      <guid isPermaLink="true">https://6ix.com/company/hikma-pharmaceuticals-plc/news/bio-thera-solutions-and-hikma-pharmaceuticals-announce-fda-approval-of-starjemzar-ustekinumab-hmny-injection-a-biosimilar-referencing-stelarar-ustekinumab-injection-1</guid>
      <pubDate>Tue, 27 May 2025 06:00:00 GMT</pubDate>
      <description>Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing Stelara® (ustekinumab) Injection. STARJEMZA® is Bio-Thera&apos;s third FDA approved product.</description>
    </item>
    <item>
      <title>Medium-term Group guidance ahead of US site visit</title>
      <link>https://6ix.com/company/hikma-pharmaceuticals-plc/news/medium-term-group-guidance-ahead-of-us-site-visit</link>
      <guid isPermaLink="true">https://6ix.com/company/hikma-pharmaceuticals-plc/news/medium-term-group-guidance-ahead-of-us-site-visit</guid>
      <pubDate>Thu, 15 May 2025 11:00:00 GMT</pubDate>
      <description>Medium-term Group guidance ahead of US site visit.</description>
    </item>
  </channel>
</rss>